These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34528610)

  • 21. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapies for active rheumatoid arthritis after methotrexate failure.
    O'Dell JR; Mikuls TR; Taylor TH; Ahluwalia V; Brophy M; Warren SR; Lew RA; Cannella AC; Kunkel G; Phibbs CS; Anis AH; Leatherman S; Keystone E;
    N Engl J Med; 2013 Jul; 369(4):307-18. PubMed ID: 23755969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of combination therapy with methotrexate and sinomenine or leflunomide for active rheumatoid arthritis: A randomized controlled clinical trial.
    Huang RY; Pan HD; Wu JQ; Zhou H; Li ZG; Qiu P; Zhou YY; Chen XM; Xie ZX; Xiao Y; Huang QC; Liu L
    Phytomedicine; 2019 Apr; 57():403-410. PubMed ID: 30851515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medical therapy: where are we now?
    Resman-Targoff BH
    Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S11-8. PubMed ID: 16960243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [DMARDs (disease-modifying antirheumatic drugs)].
    Tanaka E; Yamanaka H
    Nihon Rinsho; 2013 Jul; 71(7):1199-206. PubMed ID: 23961667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.
    van Vollenhoven RF; Ernestam S; Geborek P; Petersson IF; Cöster L; Waltbrand E; Zickert A; Theander J; Thörner A; Hellström H; Teleman A; Dackhammar C; Akre F; Forslind K; Ljung L; Oding R; Chatzidionysiou A; Wörnert M; Bratt J
    Lancet; 2009 Aug; 374(9688):459-66. PubMed ID: 19665644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
    Finckh A; Dehler S; Gabay C;
    Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
    van der Kooij SM; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; van Zeben D; Kerstens PJ; Gerards AH; van Groenendael JH; Hazes JM; Breedveld FC; Allaart CF; Dijkmans BA
    Ann Rheum Dis; 2007 Oct; 66(10):1356-62. PubMed ID: 17293364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.
    Wisłowska M; Jakubicz D
    Rheumatol Int; 2007 May; 27(7):641-7. PubMed ID: 17235556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug combinations with methotrexate to treat rheumatoid arthritis.
    Rath T; Rubbert A
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S52-7. PubMed ID: 21044434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.
    Donahue KE; Gartlehner G; Jonas DE; Lux LJ; Thieda P; Jonas BL; Hansen RA; Morgan LC; Lohr KN
    Ann Intern Med; 2008 Jan; 148(2):124-34. PubMed ID: 18025440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
    Sizova L
    Br J Clin Pharmacol; 2008 Aug; 66(2):173-8. PubMed ID: 18537958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate.
    O'Dell JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S53-8. PubMed ID: 10589358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
    Mittal N; Sharma A; Jose V; Mittal R; Wanchu A; Bambery P
    Rheumatol Int; 2012 Mar; 32(3):743-8. PubMed ID: 21161534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.
    Katchamart W; Trudeau J; Phumethum V; Bombardier C
    Cochrane Database Syst Rev; 2010 Apr; 2010(4):CD008495. PubMed ID: 20393970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
    Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.